Seeking Alpha

Gilead Pharmaceuticals (GILD +3%) tacks on another gain today, adding to yesterday's +4% run on...

Gilead Pharmaceuticals (GILD +3%) tacks on another gain today, adding to yesterday's +4% run on the back of yesterday's update on ION-1, a Phase 3 clinical trial evaluating a combination of sofosbuvir and ledipasvir with and without ribavirin for treating the hepatitis C virus infection. A review by the study's Data and Safety Monitoring Board concluded that the trial should continue without modification. ISI says the treatment could see sales of $6B or more during either 2014 or 2015.
Comments (1)
  • zorro2828
    , contributor
    Comments (537) | Send Message
     
    this stock is like CELG and BIIB .. they are on fire with full pipes and lots of great trials and opportunity to grow revenue exponentially .. I bought more and will continue to add more shares...
    28 Mar 2013, 02:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|